Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Advises Manufacturers To Test For Nitrosamines In All APIs, Drug Products

Sep 02 2020

• By Bowman Cox

chemistry

Related Content

The EU's Top Valsartan Lesson: Closely Examine Active Substance Manufacturing Processes

Jun 26 2020

FDA Warning Letter Blasts Mylan’s Continued Lax Impurity Controls for APIs

Sep 01 2020

Enforcing A Belated Chemistry Lesson – The Nitrosamines In Sartans Saga

Aug 22 2019

EMA Tells Firms To Evaluate OTCs For Carcinogenic Nitrosamines

Sep 27 2019

US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations

Apr 02 2020

Additional Topics

International United States FDA Regulation Guidance Documents Advertising, Marketing & Sales Commercial Compliance Drug Approval Standards Ingredients Manufacturing OTC Drugs Policy Safety Consumer BioPharmaceutical

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window